Prevalence of Disease and Relationships between Laboratory Phenotype and Bleeding Severity in Platelet Primary Secretion Defects
Open Access
- 2 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e60396
Abstract
The prevalence of platelet primary secretion defects (PSD) among patients with bleeding diathesis is unknown. Moreover, there is paucity of data on the determinants of bleeding severity in PSD patients. To determine the prevalence of PSD in patients with clinical bleeding and to study the relationships between the type of platelet defect and bleeding severity. Data on patients referred for bleeding to the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan (Italy) in the years between 2008 and 2012 were retrieved to study the prevalence of PSD. Demographic, clinical and laboratory information on 32 patients with a diagnosis of PSD was used to compare patients with or without associated medical conditions and to investigate whether or not the type and extension of platelet defects were associated with the bleeding severity score (crude and age-normalized) or with the age at first bleeding requiring medical attention. The estimated prevalence of PSD among 207 patients with bleeding diathesis and bleeding severity score above 4 was 18.8% (95% confidence interval [CI]: 14.1–24.7%). Patients without associated medical conditions had earlier age of first bleeding (18 vs 45 years; difference: -27 years; 95% CI: -46 to -9 years) and different platelet functional defect patterns (Fisher's exact test of the distribution of patterns, P = 0.007) than patients with accompanying medical conditions. The type and extension of platelet defect was not associated with the severity of bleeding. PSD is found in approximately one fifth of patients with clinical bleeding. In patients with PSD, the type and extension of laboratory defect was not associated with bleeding severity.Keywords
This publication has 26 references indexed in Scilit:
- Advances in our understanding of the molecular basis of disorders of platelet functionJournal of Thrombosis and Haemostasis, 2011
- Diagnostic evaluation of platelet function disordersBlood Reviews, 2011
- Molecular defects of the platelet P2 receptorsPurinergic Signalling, 2011
- ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disordersJournal of Thrombosis and Haemostasis, 2010
- Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter studyJournal of Thrombosis and Haemostasis, 2006
- Inherited Defects in Platelet Signaling MechanismsSeminars in Thrombosis and Hemostasis, 2004
- Disorders of platelet functionCritical Reviews in Oncology/Hematology, 1996
- Early presence of activated (‘exhausted’) platelets in malignant tumors (breast adenocarcinoma and malignant melanoma)European Journal of Cancer and Clinical Oncology, 1989
- A defect of platelet release reaction in a patient with SLE: Impaired platelet aggregation induced by phorbol ester with a normal phosphorylation of 40K proteinScandinavian Journal of Haematology, 1986
- The platelet defect in leukemia. Platelet ultrastructure, adenine nucleotide metabolism, and the release reaction.Journal of Clinical Investigation, 1975